Cannae (CNNE) vs. iShares NASDAQ Biotechnology Index (IBB) Head to Head Survey
Cannae (NYSE: CNNE) and iShares NASDAQ Biotechnology Index (NASDAQ:IBB) are both finance companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.
Earnings & Valuation
This table compares Cannae and iShares NASDAQ Biotechnology Index’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cannae||$1.34 billion||0.96||$650.00 million||$1.62||11.23|
|iShares NASDAQ Biotechnology Index||N/A||N/A||N/A||$30.28||3.64|
This table compares Cannae and iShares NASDAQ Biotechnology Index’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|iShares NASDAQ Biotechnology Index||N/A||N/A||N/A|
This is a breakdown of current ratings and price targets for Cannae and iShares NASDAQ Biotechnology Index, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|iShares NASDAQ Biotechnology Index||0||0||1||0||3.00|
Institutional and Insider Ownership
69.9% of Cannae shares are held by institutional investors. Comparatively, 27.3% of iShares NASDAQ Biotechnology Index shares are held by institutional investors. 6.0% of Cannae shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
Cannae has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, iShares NASDAQ Biotechnology Index has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.
iShares NASDAQ Biotechnology Index pays an annual dividend of $0.32 per share and has a dividend yield of 0.3%. Cannae does not pay a dividend. iShares NASDAQ Biotechnology Index pays out 1.1% of its earnings in the form of a dividend.
Cannae beats iShares NASDAQ Biotechnology Index on 8 of the 12 factors compared between the two stocks.
Cannae Holdings, Inc. is a diversified holding company. The Company has investments in a variety of industries including Restaurants, Technology Enabled Healthcare Services, Financial Services and more. The Company holds majority and minority equity investment stakes in a number of entities, including Ceridian Holdings, LLC, American Blue Ribbon Holdings, and LLC and T-System Holding LLC.
About iShares NASDAQ Biotechnology Index
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.
Receive News & Ratings for Cannae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cannae and related companies with MarketBeat.com's FREE daily email newsletter.